High-value markets RELIGN operates in medical equipment manufacturing with a focus on arthroscopy and resection, presenting a potential entry point for hospitals and specialty clinics seeking advanced single-system solutions that reduce intraoperative equipment exchanges and streamline procedures.

Innovative platform The Tricera System combines ablation, coagulation, tissue resection, bone cutting, and fluid management in one device, offering surgeons enhanced control and efficiency, which can be positioned to win procurement deals with institutions pursuing cutting-edge arthroscopic technology.

Strategic ownership Relign was acquired by Zimmer Biomet in January 2021, indicating backing by a major medical device conglomerate and potential alignment with Zimmer Biomet’s sales channels, service networks, and favorable reimbursement strategies.

Growth potential With funding of $30M but current revenue under $1M, there is an opportunity to target growth-stage customers and early-adopter accounts in sports medicine and orthopedics that value scalable, All-in-One solutions and long-term vendor partnerships.

Evidence of adoption The emphasis on R&D and surgeon feedback signals a product roadmap aligned with clinical demand; sales outreach can leverage clinician testimonials, case studies, and pilot data to establish credibility with hospital systems and private clinics.